Dr. Formenti is the recipient of the Healthcare Disparity Research Award for her work on microbiome and immune correlates.

WCMC guided Prostate SBRT, to start in 2020. She also received a Level 3 DoD award for Breaking through immune resistance of HR+ Breast Cancer and a Level 2 DoD award for the study- Converting HR+ Breast Cancer into an Individualized Vaccine.

Dr. Josephine Kang was awarded the Basic/Translational Science Award from ASTRO and the abstract was featured in Best of ASTRO 2019 meeting - VISTA Blockade Immunotherapy in a Multi-Modal Approach to Triple Negative Breast Cancer (TNBC) in MICE and IMPACT on Microbiome. She was also awarded a R01 for PSMA PET/MR guided Prostate SBRT, to start in 2020. She also received WCMC- Abby J Cohen clinical scholar award for her work on microbiome and immune correlates.

We have six IITs in pipeline which should be approved very soon- Prostate Radio Ablation Guided by MRI Acquisition in metastatic prostate cancer (PRAGMA), The Irradiated Breast Tumor Cavity (IORT), Personalized Second Chance Breast Conservation (PSCBC), Combined Immunotherapies in Metastatic ER+ breast cancer (CIMER), Salvage HYPOfractionated RadioTherapy for Prostate Cancer (Salvage HYPORT Trial) and Phase II study of PSMA PET/MR guided SBRT with SIB for high risk prostate cancer.

Dr. Sandra Demaria was awarded the John M. Yahas Award by the Dept. of Radiation Oncology, University of Pennsylvania for impactful contributions to the field of Radiation Oncology/Biology. Dr. Demaria is also the Chairperson-Elect to the Steering Committee of the ACR Cancer Immunology Working Group (CIMM). Dr. Demaria served as the Chair for the 34th Annual Meeting for the Society for the Immunotherapy of Cancer (SITC) 2019.

Dr. Higinia Cardenes was invited to be a member of the 2019 ASTRO International Scientific Advisory Board. She served as a member of the Working Group on the Screening for Hepatocellular Carcinoma (HCC) and intrahepatic cholangiocarcinomas.

Dr. Onyinye Balogun received the 2019 Global Health Faculty Award by ARRO in recognition of her mentorship of the trainees in the Radiation Oncology community as well as commitment to the service of the patients.

Wishing you all Happy Holidays and a splendid 2020!

**ROCRO Mission Statement**

ROCRO’s mission is to be a high impact clinical research program focusing on Radiation Therapy and Immunotherapy. One of our goals is to increase extra mural funding for the clinical trials. The office aims to open multiple investigator initiated trials (IITs) and publish high impact manuscripts with the clinical data. The office plans to initiate at least two cooperative group trials as a lead institution in next five years. We are constantly improving visibility of our clinical trials to enhance patient enrollments.